| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 29.24B | 28.39B | 25.90B | 23.06B | 16.65B | 9.66B | 
| Gross Profit | 23.43B | 7.72B | 25.31B | 5.81B | 6.10B | 9.66B | 
| EBITDA | 6.41B | 5.34B | 5.84B | 4.54B | 2.66B | 2.64B | 
| Net Income | 4.35B | 4.07B | 3.37B | 2.66B | 1.65B | 1.49B | 
| Balance Sheet | ||||||
| Total Assets | 0.00 | 33.26B | 25.46B | 22.04B | 13.53B | 5.96B | 
| Cash, Cash Equivalents and Short-Term Investments | 16.64B | 16.64B | 9.85B | 7.11B | 6.26B | 1.33B | 
| Total Debt | 0.00 | 1.02B | 4.90B | 5.03B | 657.52M | 513.88M | 
| Total Liabilities | -26.16B | 7.10B | 11.16B | 11.40B | 5.90B | 2.63B | 
| Stockholders Equity | 26.16B | 26.16B | 14.29B | 10.64B | 7.64B | 3.25B | 
| Cash Flow | ||||||
| Free Cash Flow | 0.00 | 4.12B | 4.97B | 1.11B | 2.72B | 1.51B | 
| Operating Cash Flow | 0.00 | 4.42B | 5.08B | 1.30B | 2.97B | 1.72B | 
| Investing Cash Flow | 0.00 | -6.83B | -3.27B | -8.93B | -1.60B | -242.49M | 
| Financing Cash Flow | 0.00 | 2.88B | -662.00M | 3.33B | 2.33B | -1.32B | 
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth | 
|---|---|---|---|---|---|---|---|
| ― | ₹313.69B | 38.50 | ― | 0.73% | 17.09% | 21.20% | |
| ― | ₹522.85B | 29.38 | ― | 1.98% | 8.11% | 10.73% | |
| ― | ₹345.38B | 51.50 | ― | 1.35% | -1.19% | -17.92% | |
| ― | ₹130.19B | 29.81 | ― | 0.37% | ― | ― | |
| ― | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
| ― | ₹1.42T | 28.56 | ― | 3.14% | 3.30% | 36.78% | |
| ― | ₹323.19B | ― | ― | ― | 120.98% | 66.43% | 
Indegene Limited has announced an upcoming Investor Presentation scheduled for October 6, 2025, as part of its ongoing engagement with analysts and investors. This presentation, which has been made available on the company’s website, is part of Indegene’s strategic efforts to communicate its business developments and future plans, potentially impacting its market positioning and stakeholder relations.
Indegene Limited has announced a scheduled meeting with investors and analysts on October 6, 2025, as part of their regulatory obligations. This meeting will feature key company executives, including the Chairman and CEO, Manish Gupta, and CFO, Suhas Prabhu, providing an opportunity for stakeholders to engage with the company’s senior management. The meeting aims to update stakeholders on corporate developments, although no unpublished price-sensitive information will be disclosed.
Indegene Limited has announced the publication of its financial results for the quarter ending June 30, 2025, in prominent newspapers. This move aligns with regulatory requirements and aims to ensure transparency and accessibility of financial information for stakeholders, potentially impacting investor confidence and market positioning.